Advances in molecular screening technology have enabled the
identification of novel synthetic lethal gene combinations, enabling the development
of lead candidates that leverage the aforementioned phenomenon to offer
therapeutic benefit.
Roots
Analysis is pleased to
announce the publication of its recent study, titled, “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on
DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways”.
The report features an extensive study of the
current market landscape, offering an informed opinion on the likely adoption
of such compact diagnostic devices, over the next decade. The report features
an in-depth analysis, highlighting the capabilities of various stakeholders
engaged in this domain. In addition to other elements, the study includes:
§
A detailed assessment of the current market landscape,
providing information on drug developer(s) phase of development, type of
molecule, type of therapy, type of synlet target, target patient segment, key
therapeutic area(s), target indication(s), and route of administration. In
addition, the chapter includes a list of screening platforms that are being
used by industry players to study synlet interactions between gene pairs.
§
Detailed profiles of players that are engaged in the
development of synthetic lethality-based drugs, featuring a brief overview of
the company, its financial information (if available), detailed profiles of
their respective lead drug candidates, and an informed future outlook.
§
An analysis of the prevalent and emerging trends in this
domain, as represented on the social media platform, Twitter, posted during the
period 2010-2019 (till May), highlighting the historical trend of tweets, most
prolific contributors, frequently discussed synlet targets, popular disease
indications and a multivariate tweet benchmark analysis.
§
An analysis of close to 700 peer-reviewed scientific
articles related to synthetic lethality, published during the period 2017-2019
(till May), highlighting the research focus within this niche industry segment.
§
An analysis of various abstracts presented at the American
Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May),
highlighting several parameters, such as year of (abstract) publication,
popular drugs, synlet targets, target cancer indications, popular authors,
author designations, industry type (industry and academia) and most active
organizations (in terms of number of published abstracts).
§
An in-depth analysis of close to 750 grants that have been
awarded to research institutes engaged in projects related to synthetic
lethality, between 2014 and 2019 (till May), highlighting various important
parameters associated with grants, such as year of award, support period,
amount awarded, funding institute, administration institute center, funding
institute center, funding mechanism, spending categorization, grant type,
responsible study section, focus area, type of recipient organization and
prominent program officers.
§
An analysis of the investments made into companies that
have proprietary synthetic lethality-based drugs / screening platforms,
including seed financing, venture capital financing, debt financing, grants,
capital raised from IPOs and subsequent offerings.
§
An in-depth benchmark analysis of over 230 synlet targets
identified from various credible sources (research publications, government
fundings, clinical studies, recent news / tweets and abstracts presented in
global conferences), highlighting targets that have already been validated in
clinical studies, preclinical studies and early-stage research (cases where
there is no lead (therapeutic) candidate being investigated). Further, it
highlights the long-term opportunities (for drug developers) associated with
individual targets, based on their popularity across different portals.
§
An analysis of the role of innovative companion diagnostics
in synthetic lethality on the basis of several parameters, such as synlet
target, drug candidate(s) being investigated, target biomarker(s), target
disease indication(s) and assay technique used. It also includes case studies,
highlighting those companion diagnostic tests that are available and are being
used to evaluate the therapeutic efficiency of approved PARP inhibitors using
the principle of synthetic lethality.
§
A detailed market
forecast, featuring analysis of the current and projected future opportunity
across key market segments (listed below)
§
Type of Molecule
§ Small
Molecule
§ Biologic
§
Target Indication
§ Breast
Cancer
§ Cervical
/ Anogenital Cancer
§ Diabetic
Macular Edema
§ Gastric
Cancer
§ Lung
Cancer
§ Ovarian
Cancer
§ Renal
Cell Cancer
§
Synlet Target
§
APE / REF-1
§
CHK1
§
GLS1
§
PARP
§
Polθ
§
WEE1
§
Route of Administration
§ Oral
§ Intravenous
§
Key Geographical Regions
§
North America
§
Europe
§
Asia-Pacific
§
Rest of the World
§
Transcripts of
interviews held with the following senior level representatives of stakeholder
companies
§
Simon Boulton (Vice President, Science Strategy, Artios Pharma)
§
Yi Xu (Associate Director, Business Development, IMPACT Therapeutics)
§
Norbert Perrimon (Professor, Department of Genetics, Harvard Medical School)
§
Vivek Dharwal (Professor, Department of Biochemistry, Panjab University)
§
Alfred Nijkerk (Chief Executive Officer, UbiQ)
Key
companies covered in the report
§
AbbVie
§
AstraZeneca
§
AtlasMedx
§
BeiGene
§
Chordia Therapeutics
§
Clovis Oncology
§
GlaxoSmithKline
§
IDEAYA Biosciences
§
Mission Therapeutics
§
Pfizer
§
Repare Therapeutics
§
Sierra Oncology
§
SyntheX Labs
For
more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html
Other Recent Offerings
1.
Global
T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
2.
Neoantigen
Targeted Therapies Market, 2019-2030
3.
Cancer
Biomarkers Market: Focus On TMB, MSI / MMR and TILS Testing, 2019 – 2030
4.
Companion
Diagnostics Market (2nd Edition), 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
